NEW STUDY LINKS HIGH-POTENCY CANNABIS TO INCREASED RISK OF PSYCHOSIS AND SCHIZOPHRENIA

A recent U.S. study warns that cannabis products with high THC concentrations could significantly raise the risk of developing mental health issues, including psychosis and schizophrenia. The findings highlight a growing concern over the increasing potency of cannabis on the market.

A new study has found that cannabis products containing high concentrations of THC (delta-9-tetrahydrocannabinol) may significantly increase the risk of psychosis, schizophrenia, and addiction. This warning comes as the potency of cannabis products available today far surpasses that of the traditional plant.

While cannabis is largely illegal in the European Union, an estimated 4.3 million people use it daily or almost daily. Products range from smoking marijuana to consuming edibles and concentrated liquids like hash oil in vapes. The primary psychoactive compound in all these is THC, which produces the "high."

According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the average THC concentration in cannabis resin was 23% in 2023, more than double the 11% found in herbal cannabis.

Researchers in the U.S. reviewed data from 99 studies published between 1977 and 2023, which collectively included over 220,000 people. Their analysis revealed a link between high-concentration THC use and psychosis and schizophrenia, particularly within 12 hours of use. Dr. Jonathan Samet, one of the study's authors, called these results "a serious warning."

Although the study's findings on more common mental health issues like anxiety and depression were mixed, the evidence suggests a clear link between high-potency THC and psychotic symptoms. Dr. Samet stressed the importance of closely monitoring the health consequences of these powerful products.

The EMCDDA has also noted that frequent and long-term cannabis use is more likely to lead to health problems, including respiratory issues, addiction, and psychotic symptoms.

The researchers believe their findings could help inform future regulations on cannabis, especially in places like the U.S. where these products are widely and legally available. Dr. Samet advises that both doctors and consumers need to be aware of the risks, especially for individuals with pre-existing mental health conditions.